194 related articles for article (PubMed ID: 21887218)
1. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI.
Eliyahu E; Wolfson T; Ge Y; Jepsen KJ; Schuchman EH; Simonaro CM
PLoS One; 2011; 6(8):e22447. PubMed ID: 21887218
[TBL] [Abstract][Full Text] [Related]
2. Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses.
Schuchman EH; Ge Y; Lai A; Borisov Y; Faillace M; Eliyahu E; He X; Iatridis J; Vlassara H; Striker G; Simonaro CM
PLoS One; 2013; 8(1):e54459. PubMed ID: 23365668
[TBL] [Abstract][Full Text] [Related]
3. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses.
Simonaro CM; Haskins ME; Schuchman EH
Lab Invest; 2001 Sep; 81(9):1319-28. PubMed ID: 11555679
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy improves joint motion and outcome of the 12-min walk test in a mucopolysaccharidosis type VI patient previously treated with bone marrow transplantation.
Sohn YB; Park SW; Kim SH; Cho SY; Ji ST; Kwon EK; Han SJ; Oh SJ; Park YJ; Ko AR; Paik KH; Lee J; Lee DH; Jin DK
Am J Med Genet A; 2012 May; 158A(5):1158-63. PubMed ID: 22495825
[TBL] [Abstract][Full Text] [Related]
5. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses.
Simonaro CM; Ge Y; Eliyahu E; He X; Jepsen KJ; Schuchman EH
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):222-7. PubMed ID: 20018674
[TBL] [Abstract][Full Text] [Related]
6. Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval.
Auclair D; Hein LK; Hopwood JJ; Byers S
Pediatr Res; 2006 Apr; 59(4 Pt 1):538-43. PubMed ID: 16549525
[TBL] [Abstract][Full Text] [Related]
7. Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study.
Horovitz DDG; Leão EKEA; Ribeiro EM; Martins AM; Barth AL; Neri JICF; Kerstenetzky M; Siqueira ACM; Ribeiro BFR; Kim CA; Santos FC; Franco JFS; Lichtvan LCL; Giuliani LR; Rodrigues MDCS; Bonatti RCF; Teixeira TB; Gonçalves A; Lourenço CM; Pereira ASS; Acosta AX
Mol Genet Metab; 2021 May; 133(1):94-99. PubMed ID: 33678523
[TBL] [Abstract][Full Text] [Related]
8. Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI.
Auclair D; Hopwood JJ; Lemontt JF; Chen L; Byers S
Mol Genet Metab; 2007 Aug; 91(4):352-61. PubMed ID: 17544310
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy.
Garcia P; Phillips D; Johnson J; Martin K; Randolph LM; Rosenfeld H; Harmatz P
Mol Genet Metab; 2021 May; 133(1):100-108. PubMed ID: 33775523
[TBL] [Abstract][Full Text] [Related]
10. Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI.
Byers S; Nuttall JD; Crawley AC; Hopwood JJ; Smith K; Fazzalari NL
Bone; 1997 Nov; 21(5):425-31. PubMed ID: 9356736
[TBL] [Abstract][Full Text] [Related]
11. Retrospective chart review of urinary glycosaminoglycan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses.
Jones SA; Marsden D; Koutsoukos T; Sniadecki J; Tylee K; Phillippo S; Kakkis E
Mol Genet Metab; 2020 Aug; 130(4):255-261. PubMed ID: 32563631
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study.
McGill JJ; Inwood AC; Coman DJ; Lipke ML; de Lore D; Swiedler SJ; Hopwood JJ
Clin Genet; 2010 May; 77(5):492-8. PubMed ID: 19968667
[TBL] [Abstract][Full Text] [Related]
13. Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats.
Turner CT; Hopwood JJ; Bond CS; Brooks DA
Mol Genet Metab; 1999 Jul; 67(3):194-205. PubMed ID: 10381327
[TBL] [Abstract][Full Text] [Related]
14. Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment.
Frohbergh M; Ge Y; Meng F; Karabul N; Solyom A; Lai A; Iatridis J; Schuchman EH; Simonaro CM
PLoS One; 2014; 9(6):e100882. PubMed ID: 24964042
[TBL] [Abstract][Full Text] [Related]
15. Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy.
Pal AR; Mercer J; Jones SA; Bruce IA; Bigger BW
PLoS One; 2018; 13(9):e0203216. PubMed ID: 30226843
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow transplantation in newborn rats with mucopolysaccharidosis type VI: biochemical, pathological, and clinical findings.
Simonaro CM; Haskins ME; Kunieda T; Evans SM; Visser JW; Schuchman EH
Transplantation; 1997 May; 63(10):1386-93. PubMed ID: 9175798
[TBL] [Abstract][Full Text] [Related]
17. Structural, compositional, and biomechanical alterations of the lumbar spine in rats with mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome).
Lai A; Simonaro CM; Schuchman EH; Ge Y; Laudier DM; Iatridis JC
J Orthop Res; 2013 Apr; 31(4):621-31. PubMed ID: 23192728
[TBL] [Abstract][Full Text] [Related]
18. Up to five years experience with 11 mucopolysaccharidosis type VI patients.
Brands MM; Oussoren E; Ruijter GJ; Vollebregt AA; van den Hout HM; Joosten KF; Hop WC; Plug I; van der Ploeg AT
Mol Genet Metab; 2013 May; 109(1):70-6. PubMed ID: 23523338
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
[TBL] [Abstract][Full Text] [Related]
20. Genotypic-phenotypic features and enzyme replacement therapy outcome in patients with mucopolysaccharidosis VI from Turkey.
Kılıç M; Dursun A; Coşkun T; Tokatlı A; Özgül RK; Yücel-Yılmaz D; Karaca M; Doğru D; Alehan D; Kadayıfçılar S; Genç A; Turan-Dizdar H; Gönüldaş B; Savcı S; Sağlam M; Aksoy C; Arslan U; Sivri HS
Am J Med Genet A; 2017 Nov; 173(11):2954-2967. PubMed ID: 28884960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
